UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 24, 2009
PHARMASSET, INC.
(Exact Name of Registrant as Specified in its Charter)
| Delaware | 001-33428 | 98-0406340 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
| 303-A College Road East Princeton, NJ |
08540 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (609) 613-4100
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01. | Other Events. |
On April 24, 2009, Pharmasset, Inc. (the “Company”) issued a press release announcing the dosing of the first patient in a Phase 2b study of R7128, a nucleoside polymerase inhibitor in development for the treatment of patients chronically infected with the hepatitis C virus (“HCV”). R7128 is being developed by F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, “Roche”) and the Company. This trial is expected to evaluate the dose and duration of treatment of R7128 in combination with the existing standard of care (PEGASYS® (peginterferon alfa-2a) and COPEGUS® (ribavirin) in HCV patients who have not been treated previously. The dosing of the first patient in this study also triggered a $10.0 million milestone payment to the Company from Roche. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and incorporated by reference into this Current Report on Form 8-K. The press release shall be deemed filed with, and not furnished to, the Securities and Exchange Commission.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
| 99.1* | Pharmasset, Inc. Press Release dated April 24, 2009. |
| * | Pursuant to General Instruction B.2 of Form 8-K, the information contained in Exhibit 99.1 shall be deemed filed with, and not furnished to, the Securities and Exchange Commission. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PHARMASSET, INC. | ||||
| Date: April 29, 2009 | By: | /s/ Kurt Leutzinger | ||
| Name: | Kurt Leutzinger | |||
| Title: | Chief Financial Officer | |||
EXHIBIT INDEX
| Exhibit |
Description of Exhibit | |
| 99.1 | Pharmasset, Inc. Press Release dated April 24, 2009. |